Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glipizide GITS (Gastrointestinal Therapeutic System) is an oral blood-glucose-lowering drug of the sulfonylurea class formulated as a once-a-day controlled release tablet. It works by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The insulinotropic response to meals is enhanced with glipizide GITS administration in diabetic patients. The medication is contained within a non-absorbable shell specially designed to slowly release the drug so the body can absorb it gradually, maintaining effective plasma concentrations throughout the 24-hour dosing interval with less peak-to-trough fluctuation than twice-daily dosing of immediate-release glipizide.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glipizide GITS.